Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Pfizer Inc | 22.03M | $49.0M | 9.00% | -- | 2026-03-31 |
| BlackRock, Inc. | 19.09M | $46.0M | 7.80% | +1.42M | 2026-03-31 |
| TPG GP A, LLC | 18.72M | $45.0M | 7.65% | -- | 2026-03-31 |
| STATE STREET CORP | 8.66M | $21.0M | 3.54% | +5.90M | 2026-03-31 |
| PRIMECAP MANAGEMENT CO/CA/ | 8.38M | $20.0M | 3.42% | +240.0K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.92M | $16.0M | 2.83% | -- | 2026-03-31 |
| CITADEL ADVISORS LLC | 6.89M | $16.0M | 2.81% | -5.32M | 2026-03-31 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.38M | $13.0M | 2.20% | +2.17M | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.12M | $10.0M | 1.68% | +191.3K | 2026-03-31 |
| Frazier Life Sciences Management, L.P. | 3.80M | $9.0M | 1.55% | -72.1K | 2026-03-31 |
